Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-145.34	-141.41	-19.82	-98.78	-76.36	-54.12
Depreciation & Amortization	0.71	0.74	0.67	0.67	0.6	0.5
Share-Based Compensation	17.02	15.56	14.89	13.87	7.64	5.67
Other Operating Activities	13.64	7.1	-108.63	28.77	-1.68	-0.69
Operating Cash Flow	-113.98	-118	-112.89	-55.48	-60.91	-48.63
Capital Expenditures	-0.11	-0.11	-1.6	-2.89	0	-0.39
Acquisitions	0	0	107.38	0	0	0
Change in Investments	44.39	-28.5	0	1.47	-0.74	4.27
Investing Cash Flow	44.28	-28.61	105.77	-1.42	-0.74	3.88
Share Issuance / Repurchase	26.88	26.63	66.27	1.2	109.22	67.97
Debt Issued / Paid	0.17	0	58.51	40.26	0	0
Other Financing Activities	-	-	-0.04	-0.15	-	-
Financing Cash Flow	27.06	26.63	124.74	41.31	109.22	67.97
Net Cash Flow	-42.65	-119.98	117.62	-15.58	47.57	23.22
Free Cash Flow	-114.09	-118.11	-114.49	-58.37	-60.91	-49.02
Free Cash Flow Margin	-403.33%	-381.14%	-449.36%	-380.36%	-3545.52%	-
Free Cash Flow Per Share	-2.01	-2.20	-2.93	-1.59	-2.23	-3.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).